Indications and uses
Varicose Veins, Vomiting
Varicose Veins, Vomiting
Store in a cool dark place
CARDUUS MARIANUS HPUS 1X and higher
Varicose Veins, Vomiting
Condition listed above or as directed by the physician
Adults- Take 4 or 6 Pellets by mouth, three times daily or as suggested by physician. Children 2 years and older- take 1/2 the adult dose.
This product is to be used for self-limiting conditions
If symptoms do not improve in 4 days, or worsen, discontinue use and seek assistance of health professional
As with any drug, if you are pregnant, or nursing a baby, seek professional advice before taking this product
Keep this and all medication out of reach of children
Do not use if capseal is broken or missing.
Close the cap tightly after use.
Sucrose
Store in a cool dark place
www.rxhomeo.com | 1.888.2796642 | info@rxhomeo.com
Rxhomeo, Inc 9415 Burnet Road, Suite 312, Austin, TX 78758
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 15631-0112-0 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2a5d-f424-e053-dadaa90a57ce | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
| 15631-0112-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2a5d-f424-e053-dadaa90a57ce | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
| 15631-0112-2 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2a5d-f424-e053-dadaa90a57ce | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
| 15631-0112-3 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2a5d-f424-e053-dadaa90a57ce | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
| 15631-0112-4 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2a5d-f424-e053-dadaa90a57ce | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
| 15631-0112-5 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-2a5d-f424-e053-dadaa90a57ce | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 15631-0112-0 | CARDUUS MARIANUS | 100 in 1 PACKAGE | PELLET | 100 | 1 | |
| 15631-0112-1 | CARDUUS MARIANUS | 200 in 1 PACKAGE | PELLET | 200 | 1 | |
| 15631-0112-2 | CARDUUS MARIANUS | 400 in 1 PACKAGE | PELLET | 400 | 1 | |
| 15631-0112-3 | CARDUUS MARIANUS | 750 in 1 PACKAGE | PELLET | 750 | 1 | |
| 15631-0112-4 | CARDUUS MARIANUS | 2500 in 1 PACKAGE | PELLET | 2500 | 1 | |
| 15631-0112-5 | CARDUUS MARIANUS | 12500 in 1 PACKAGE | PELLET | 12500 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 15631-0112 | CARDUUS MARIANUS PELLET [RXHOMEO PRIVATE LIMITED D.B.A. RXHOMEO, INC] | 1 | Legacy NDC, 6 package rows | 20151008_07a4c2a8-6896-4b7c-9dda-d9294d85d23b.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| MILK THISTLE | ACTIVE INGREDIENT | U946SH95EE | 1 | |
| MILK THISTLE | ACTIVE MOIETY | U946SH95EE | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 15631-0112 | 15631-0112-0, 15631-0112-1, 15631-0112-2, 15631-0112-3, 15631-0112-4, 15631-0112-5 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MILK THISTLE | U946SH95EE | ACTIB |
| SUCROSE | C151H8M554 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 7f9107d5-fef1-4528-ab48-a2d9f7bba67b | 07a4c2a8-6896-4b7c-9dda-d9294d85d23b | 2015-10-06 | Warnings | 7f9107d5-fef1-4528-ab48-a2d9f7bba67b 07a4c2a8-6896-4b7c-9dda-d9294d85d23b |
Adverse event summaries are temporarily unavailable. Other product information remains available.